Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

Figure 2

Combination of dabrafenib with AKTi enhances cell growth inhibition in dabrafenib sensitive (A) and resistant cell lines (B) but not in very sensitive cell lines (C). The cells were treated with increasing concentrations (1-10,000 nM) of single agent dabrafenib, single agent AKTi or the combination (1:1) for 72-120 hours to assess cell viability. Bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM. (D) Combination index values (CI) for dabrafenib and AKTi. Values less than 1 indicates synergism, CI = 1 indicates an additive effect, and CI > 1 antagonism. The bars represent the average CI value of minimum two independent experiments and the error bars represent the SEM. * p < 0.05 when single agent dabrafenib was compared to combination treatment.

Back to article page